X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

New upper extremity standard biopsy sites for diagnosis of small fiber neuropathy

Yuvraj_pawp by Yuvraj_pawp
6th August 2014
in Market Moves

Therapath LLC (www.Therapath.com),a leader in neuropathology laboratory services, has established normative values for two upper limb body sites that can now be used to evaluate 3mm punch skin biopsy specimens for Epidermal Nerve Fiber Density (ENFD) and Sweat Gland Nerve Fiber Density (SGNFD). The additional body sites were determined in an IRB approved clinical study of normal adult subjects. The new biopsy sites are defined as the Proximal Arm (Lateral surface midway between the shoulder (acromion) and the elbow) and the Distal Arm (Upper (hairy or dorsal) surface of the forearm, 5 cm above the wrist). These new sites complement the existing standardized biopsy sites at the proximal thigh, distal leg (calf) and dorsal foot. The punch skin biopsy with enumeration of the epidermal nerve fiber density is a reliable and efficient technique to assess the diagnosis of small fiber neuropathy (Joint Task Force or EFNS and PNS, J Periph Nerv Syst 2010).

 

Several studies have recently reported a decrease in epidermal nerve fiber density in a subset of patients with fibromyalgia (Oaklander et al, Pain 2013; Caro and Winter, Arthritis Rheumatol 2014; Giannoccaro, et all, Muscle Nerve 2014) concluding that skin biopsy should be considered in the diagnostic work-up of Fibromyalgia to search for Small Fiber Neuropathy. The availability of the new standard biopsy sites will enable physicians diagnose small fiber neuropathy in patients whose symptoms are confined to the upper extremities.

 

Additionally, Therapath completed analysis on the effect of age and gender on normative values for ENFD and SGNFD at all standardized biopsy sites. Therapath will use these values for diagnosis of small fiber neuropathy.

 

About Therapath Neuropathology:

 

Therapath Neuropathology, founded in 2004, is a College of American Pathology accredited (CAP) and CLIA licensed specialized laboratory. The medical team are board certified in neuropathology, academically trained and extensively published. Therapath’s focus is on research and development in the testing services for muscle biopsy, nerve biopsy with teased fiber analysis, ocular (including optic neurotis), skin epidermal nerve fiber density, sweat gland nerve fiber density, skin biopsy for CADASIL and other storage disorders as well as brain/spinal cord specimens. Therapath serves hospitals, private practitioners, reference laboratories, pharmaceutical industry, and researchers throughout all 50 states and worldwide including; Australia, Brazil, Canada, China, England, Germany, Greece, Hong Kong, Israel, Italy, Japan, Mexico, the Netherlands, and Saudi Arabia.

Previous Post

AMRI ANNOUNCES SECOND QUARTER 2014 RESULTS

Next Post

Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014

Related Posts

Market Moves

Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter

8th April 2022
Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Market Moves

Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform

29th January 2022
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Indian Pharma Industry To Grow By 9-11% In FY22- ICRA

7th January 2022
Market Moves

IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance

26th October 2021
My Personal Therapeutics and Pentavere receive EUREKA AI Therapeutics Funding to support the development of My Personal Therapeutics - digital therapeutics for Lung Cancer
Manufacturing

Consumer Health Apps and Digital Health Tools Proliferate, Improving Quality and Health Outcomes for Patients, Says New Report from IQVIA Institute

2nd August 2021
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Biopharma Market to grow at 10.6% CAGR between 2020 and 2027

3rd December 2020
Next Post

Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014

Latest News

Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In